Patient Support Line 1-866-433-8000, Monday - Friday: 8:00 AM to 8:00 PM ET
HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.
HER2-, factor de crecimiento epidérmico humano 2 negativo; HR+, receptor hormonal positivo.
HER2-, factor de crecimiento epidérmico humano 2 negativo; HR+, receptor hormonal positivo.
KISQALI is not approved for use with tamoxifen.
KISQALI no está aprobado para la administración con tamoxifeno.
Ana hasn’t come this far to stop now. Watch how KISQALI + hormone therapy give her more life for living, and why she's more than just breast cancer*
With KISQALI + hormone therapy, you can live longer, so you can spend more time doing what you love*
See what more life for living means to Jordan and how KISQALI + hormone therapy can help you.
*Time spent living with breast cancer is called overall survival, or OS, in clinical trials. Median OS is the length of time when half of the people in the trial were still alive. At an 80-month check-in, median OS was 63.9 months with KISQALI + an aromatase inhibitor (AI) vs 51.4 months with placebo + an AI.